GLP-1s

The first phase of the GLP-1 boom was defined by shortages and brand-name manufacturers sparring with compounding pharmacies. The next phase will be marked by Medicare coverage expansions and new GLP-1 pills for weight loss — two developments expected to…

As retailers, payers and drugmakers expand access to GLP-1 therapies — with companies like Amazon and Walmart launching weight management programs — the drug class is reshaping both care delivery and pharmaceutical investment strategies. That demand is influencing drug development,…

Boston-based Beth Israel Deaconess Medical Center researchers have found GLP-1 drugs were associated with fewer peptic ulcer diagnoses among patients with Type 2 diabetes. The study, published in Clinical Gastroenterology and Hepatology, analyzed EHR data from more than 66,000 adults…

The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, the latest move in a monthslong crackdown on the compounded GLP-1 market. The 503B bulks list identifies bulk drug substances outsourcing facilities can use in compounding…

Semaglutide was linked to a higher risk of a rare eye condition, nonarteritic anterior ischemic optic neuropathy, compared to another class of diabetes drugs. The study, published Feb. 12 in JAMA Ophthalmology, examined 102,361 veterans, including 11,478 who initiated semaglutide…

Health systems are finding that the biggest challenge with GLP-1 medications isn’t starting patients on therapy — it’s keeping them on it. During a panel at Becker’s Spring Chief Pharmacy Officer Summit, pharmacy and physician leaders said adherence has emerged…

Self-funded health systems have been navigating a costly GLP-1 landscape in recent years, and the issue has not seemed to lighten up — yet. Philadelphia-based Jefferson Health is one of the latest grappling with steep costs for its 65,000 employees.…

More than 130 medical, public health and patient advocacy organizations are raising concerns about recent changes to the CDC’s vaccine advisory panel, warning the updates could affect vaccine access and public confidence. The concerns follow an April 1 renewal of the Advisory…

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents with Type 2 diabetes. …

Amazon and Walmart have launched GLP-1 weight management programs within days of each other, signaling a broader shift as retailers, payers and drugmakers compete to control access to one of healthcare’s fastest-growing drug classes. Amazon’s One Medical program integrates primary…